undamentalytics Newsletter
Sign in

Serina Therapeutics, Inc. income statement

In fiscal 2025, Serina Therapeutics, Inc. reported revenue of $130,000, up 132.1% on the year before, operating income of −$24.0m (a -18478.5% margin) and net income of −$19.2m, or −$1.91 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue112000300
Cost of revenue0000000——
Gross profit1110000——
Research and development6664112713
General and administrative46877641011
Operating income−7−11−13−10−8−7−3−17−24
Interest expense————13510
Income before tax—−8−12−119115−11−19
Income tax——0−0——000
Net income−7−8−12−11−9−105−11−19
Diluted EPS−$1.07−$1.07−$1.69−$1.48−$1.17−$49.54$0.73−$1.51−$1.91
Diluted shares (average)6m7m7m7m7m—7m7m10m
EBITDA−6−11−12−9——−3−17−24

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CLDX vs SERIBIO vs SERLSTA vs SER

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Serina Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Serina Therapeutics, Inc.